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Conclusions: Performing patient-specific QA for VMAT plan by using 
MapCHECK with IMF tool shows the result of agreement between 
Eclipse plan and measurement comparable with using ArcCHECK 3D 
diode array.  
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Purpose/Objective: The purpose of this work is to determine the 
statistical correlation between 2D IMRT QA passing rates and several 
clinically relevant, anatomy-based dose errors for per patient IMRTQA. 
Materials and Methods: Thirty patients which performed QA of the 
treatment plan of the VMAT(VARIAN MedicalSystems, USA) with 
prostate cancer in the past were examined. Each planned with 10 MV 
linear accelerators (Novalis-Tx; Brain LAB) using a commercial 
treatment planning system (ECLIPSE; VARIAN Medical Systems, USA) 
and VMAT. In this study was compared with 2D or volume gamma pass 
rate and Dose Volume Histogram (DVH), and absolute dose. 2D gamma 
pass rate analysis was measured by 2D pixel ion-chamber (MatriXX; 
IBA, Germany). Volume gamma pass rate and DVH were computed by 
COMPASS MatriXX systems(IBA, Germany). The dose response data 
measured by the MatriXX(IBA, Germany) was imported to the COMPASS 
MatriXX systems, and volume gamma and DVH were calculated. The 
COMPASS MatriXX systems can perform only dose calculation by using 
imported DICOM plan data and dose response. As for the absorbed 
dose was compared with 0.6ml Farmer type ion-chamber and 
COMPASS MatriXX systems. An absorbed dose was compared with mean 
dose of the same area volume as the area volume measured by ion-
chamber of the IMRT phantom, and correlation was investigated. 
Results: A variation of 2D gamma pass rate was larger than volume 
gamma. As a result of performing comparison of 2D gamma pass rate 
and DVH, absorbed dose error was less than 5% in DVH when 2D 
gamma pass rate was more than 95% of PTV. However,even if the 
rectum and bladder were more than 95% gamma pass rate, there was 
dose error more than 5% in 40% of all measured data. There were 
correlated with absolute dose measured by 0.6ml ion-chamber and 
computed by the COMPASS MatriXX systems (p<0.01).  
Conclusions: Although IMRT Plan QA by means of 2D or volume gamma 
pass rate were suitable as objective rating of distribution, it was 
suggested that these were not suitable as clinical assessment of IMRT 
Plan.  
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Purpose/Objective: The introduction of VMAT in clinical routine can 
be limited for the complexity and time needed in pre-treatment 
verification, decreasing the number of patients that could benefit. A 
fast and reliable dosimetric device is then required. Since 2009, over 
400 patients have been treated with Volumetric modulated arc 
therapy (VMAT) at Fondazione di Ricerca e Cura 'Giovanni Paolo II' of 
Campobasso, Italy. In this study we present the three-years results of 
our patient specific QA program using the PTW seven29/Octavius 
system and our institutional guidelines for VMAT delivery.  
Materials and Methods: From June 2009 to October 2012, 410 
patients were treated with VMAT technique at our institution using 
Elekta linacs and Oncentra Masterplan TPS. Patients were divided in 
three groups: (1) 125 patients with high-modulated complex 
treatments for head-neck, rectal, endometrial and brain tumours, all 
treated with Simultaneous Integrated Boost strategy using two arcs; 
(2) 140 patients with prostate and vaginal tumours and (3) 145 
patients undergone to radiosurgery or extracranial stereotactic 
techniques for bone, liver, lung, abdominal and pelvic metastasis, 
treated by one arc. The absolute doses were measured utilizing the 
PTW Seven29 ion-chamber array and the Octavius phantom. VMAT 
plans were recalculated on phantoms representing the Octavius 
geometry and density; for each arc the doses were measured both on 
coronal and sagittal planes, for a total of 1070 measurements. 
Agreement of measured and predicted doses were evaluated using 
gamma index set at 3%/3mm. Three scalar metrics were evaluated for 
each measurement: (a) percentage of points with gamma value less 
than one (Pγ<1), (b) mean gamma (γmean), and (c) maximum gamma 
(γmax). Dose measurements at isocenter point were extracted by the 
seven29 central 0.125 cc ion chamber. 
Results: Pγ<1, γmean and γmax averaged over all treatment sites were 
96.8% ± 3.0%, 0.37 ± 0.08 and 1.58 ± 0.70, respectively. For the 
patients in group (1), Pγ<1, γmean and γmax were 95.7% ± 3.0%, 0.39 ± 
0.08 and 1.90 ± 0.62, respectively. These values reached 98.2% ± 
3.3%, 0.35 ± 0.09 and 1.13 ± 0.61 values in group (2) and 98.3% ± 2.3%, 
0.31 ± 0.08 and 1.24 ± 0.70 values in group (3). Our local confidence 
limits for Pγ<1 were determined to be 9.1% over all treatment sites, 
and 10.2%, 8.1%, and 6.2%, for patients in group 1, 2 and 3, 
respectively. Mean values and SD of ion-chamber differences between 
isocenter measured and calculated doses were -0.4% ± 2.8%, -0.7% ± 
1.6% and 0.5% ± 2.0% for group 1, 2, and 3, respectively, supplying our 
local confidence limit of 5.9%, 3.8% and 4.4%.  
Conclusions: The PTW seven29/Octavius system allows a fast and 
accurate dosimetric procedure for VMAT pre-treatment verification, 
benefiting from all the advantages of ionization chamber absolute 
dosimetry. Despite the increased complexity in VMAT treatments, our 
local confidence limits were comparable to those of AAPM TG 119.  
   
EP-1177   
Designing, coding and implementing a software solution for daily 
output QA using an Electronic Portal Imaging Device 
S. Buhl1, P. Andersson1, U. Bjelkengren1 
1University Hospital Herlev, Department of Radiophysics, Herlev, 
Denmark  
 
Purpose/Objective: In the field of radiotherapy (RT) vast resources 
are being used on quality assurance (QA) to ensure the most precise 
treatment delivery. One important parameter to control and monitor 
is the dosimetric output from the linear accelerator. In recent years 
at this institute, this has been done by weekly output measurements 
with an ion chamber in a Perspex phantom. These measurements have 
been supplemented by daily output measurements using LINACHECK 
from PTW. However, modern linear accelerators allows for such 
measurements using the onboard Electronic Portal Imaging Device 
(EPID). The purpose of this study has been to design, code and 
implement a software solution for measuring and evaluating the daily 
output on the Varian iX and Truebeam accelerators using the EPID. 
Materials and Methods: Daily warm-up and output measurement test 
patients were created for each accelerator. These consisted of four 
fields: two warm-up fields (25 x 25 cm2, 400 MU, 6 and 15 MV) and 
two output measurement fields (25 x 25 cm2, 100 MU, 6 and 15 MV) 
with the EPID positioned at SID = 100 cm and the measurements 
carried out by integrating dose over time. To collect reference data 
and allow for dosimetrically equivalent measurements, the output of 
all accelerators was measured and adjusted in water to within ± 0.3 % 
of reference values. Afterwards the integrated image mode of the 
EPID was calibrated for the clinical used D/R, followed by a dosimetric 
calibration using a 10x10 cm2 field and 100 MU. Reference data was 
then collected using the test patients. All data was exported from the 
TPS as DICOM files. An algorithm for sorting measurements, 
calculating output, beam quality, symmetry and plotting in- and cross-
line profiles was created using MATLAB. For easy accessibility and 
quick handling a graphical user interface (GUI) was also coded using 
the MATLAB GUI editor. Finally the algorithm and GUI were compiled 
to an executable, allowing the software to run independently of a 
MATLAB installation using the MATLAB Compiler Runtime (MCR). 
Several versions of the software was designed, compiled and deployed 
each targeting a specific personal group with different requirements. 
All measurements and results were saved to MATLAB data files for 
storage and easy accessibility. 
Results: A lot of energy was used in the design phase of this project 
which clearly paid out in implementation and evaluation phase, where 
only minor issues related to the software arose, being primarily coding 
errors related to e.g. saving data. As a result of this several new 
versions with error corrections or minor functionality tweaks were 
deployed over the first months of implementation. 
Conclusions: Using MATLAB for creating software to interact with data 
measured using the EPID exported via DICOM has proven itself 
possible, easy and reliable. Making in-house software gives the 
benefits of a highly customizable system alongside complete 
knowledge and control over algorithms and data handling. 
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